| Recruitment status | Completed |
| Unique ID issued by UMIN | UMIN000043275 |
| Receipt No. | R000045243 |
| Scientific Title | Functional exploratory trial of symbiotic connection between food microorganism and oligosaccharide |
| Date of disclosure of the study information | 2021/03/31 |
| Last modified on | 2022/03/08 (Ver. 3) |
| Basic information | ||
| Public title | Functional exploratory trial of symbiotic connection between food microorganism and oligosaccharide | |
| Acronym | Functional exploratory trial of symbiotic connection between food microorganism and oligosaccharide | |
| Scientific Title | Functional exploratory trial of symbiotic connection between food microorganism and oligosaccharide | |
| Scientific Title:Acronym | Functional exploratory trial of symbiotic connection between food microorganism and oligosaccharide | |
| Region |
|
|
| Condition | |||
| Condition | Healthy male/female adults | ||
| Classification by specialty |
|
||
| Classification by malignancy | Others | ||
| Genomic information | NO | ||
| Objectives | |
| Narrative objectives1 | The aim of this study is to examine some kind of effect on obesity-related indexes for elucidating the symbiotic connection between the food microorganism and oligosaccharide exploratorily, employing eighty healthy little-overweight subjects. |
| Basic objectives2 | Efficacy |
| Basic objectives -Others | |
| Trial characteristics_1 | |
| Trial characteristics_2 | |
| Developmental phase | |
| Assessment | |
| Primary outcomes | 1. Visceral fat area
2. Body fat percentage 3. Body fat mass 4. Body weight 5. Body mass index 6. Gut microbiota 7. Short chain fatty acids in blood and feces (acetic/propionic/n-butyric/iso-butyric/n-valeric/iso-valeric acids) 8. Gastrointestinal hormones (PYY, GLP-1, GIP, insulin) 9. Blood-biochemical test (Total cholesterol, HDL-cholesterol, LDL-cholesterol, triglycerides, blood glucose, and HbA1c) |
| Key secondary outcomes | |
| Base | |
| Study type | Interventional |
| Study design | |
| Basic design | Parallel |
| Randomization | Randomized |
| Randomization unit | Individual |
| Blinding | Open -no one is blinded |
| Control | Placebo |
| Stratification | |
| Dynamic allocation | |
| Institution consideration | |
| Blocking | |
| Concealment | |
| Intervention | ||
| No. of arms | 4 | |
| Purpose of intervention | Treatment | |
| Type of intervention |
|
|
| Interventions/Control_1 | Oral ingestion of pro/prebiotics for 12 weeks. | |
| Interventions/Control_2 | Oral ingestion of probiotics for 12 weeks. | |
| Interventions/Control_3 | Oral ingestion of prebiotics for 12 weeks. | |
| Interventions/Control_4 | Oral ingestion of placebo for 12 weeks. | |
| Interventions/Control_5 | ||
| Interventions/Control_6 | ||
| Interventions/Control_7 | ||
| Interventions/Control_8 | ||
| Interventions/Control_9 | ||
| Interventions/Control_10 | ||
| Eligibility | ||||
| Age-lower limit |
|
|||
| Age-upper limit |
|
|||
| Gender | Male and Female | |||
| Key inclusion criteria | 1) Male/female subjects ranging in age from 20 to 64 at informed consent.
2) Subjects ranging in BMI from 25.0 to <30.0 kg/m2. 3) Subjects who can give informed consent to participate in this trial after being provided with an explanation of the experimental protocol detail. |
|||
| Key exclusion criteria | 1) Subjects with previous/present medical history of serious diseases.
2) Subjects who contracted a digestive disease within the past two weeks, and are now under medical treatments. 3) Subjects with medical therapies for a lifestyle-related disease, such as diabetes, hypertension and dyslipidemia. 4) Subjects with milk allergy or suspicious one. 5) Pregnant, possibly pregnant during this trial, or lactating women. 6) Subjects falling into the habit of heavy smoking, excessive alcohol intake, and/or an irregular life rhythm. 7) Subjects taking steadily (not less than three times a week) in the health foods, probiotics, prebiotics, fermented milk and/or lactic acid beverages, which might affect the test results. 8) Subjects who took part in the other clinical/monitoring tests, except observing ones, within a month before giving informed consent to take part in this trial. 9) Others who have been determined as ineligible for participation in this trial, judging from the principal/sub investigator's opinions. |
|||
| Target sample size | 80 | |||
| Research contact person | |||||||
| Name of lead principal investigator |
|
||||||
| Organization | Chiyoda Paramedical Care Clinic | ||||||
| Division name | Director | ||||||
| Zip code | 101-0047 | ||||||
| Address | 2F Sanwa-Uchi-Kanda Building, 3-3-5 Uchi-Kanda, Chiyoda-ku, Tokyo 101-0047, Japan | ||||||
| TEL | 03-5297-5548 | ||||||
| cpcc-contact@cpcc.co.jp | |||||||
| Public contact | |||||||
| Name of contact person |
|
||||||
| Organization | CPCC Company Limited | ||||||
| Division name | Clinical Planning Department | ||||||
| Zip code | 101-0047 | ||||||
| Address | 4F Sanwa-Uchi-Kanda Building, 3-3-5 Uchi-Kanda, Chiyoda-ku, Tokyo 101-0047, Japan | ||||||
| TEL | 03-5297-3112 | ||||||
| Homepage URL | |||||||
| cpcc-contact@cpcc.co.jp | |||||||
| Sponsor | |
| Institute | CPCC Company Limited |
| Institute | |
| Department | |
| Funding Source | |
| Organization | Meiji Co., Ltd. |
| Organization | |
| Division | |
| Category of Funding Organization | Profit organization |
| Nationality of Funding Organization | |
| Other related organizations | |
| Co-sponsor | |
| Name of secondary funder(s) | |
| IRB Contact (For public release) | |
| Organization | Institutional Review Board of Chiyoda Paramedical Care Clinic |
| Address | 2F Sanwa-Uchi-Kanda Building, 3-3-5 Uchi-Kanda, Chiyoda-ku, Tokyo 101-0047, Japan |
| Tel | 03-5297-5548 |
| IRB@cpcc.co.jp | |
| Secondary IDs | |
| Secondary IDs | NO |
| Study ID_1 | |
| Org. issuing International ID_1 | |
| Study ID_2 | |
| Org. issuing International ID_2 | |
| IND to MHLW | |
| Institutions | |
| Institutions | |
| Other administrative information | |||||||
| Date of disclosure of the study information |
|
||||||
| Related information | |
| URL releasing protocol | |
| Publication of results | Unpublished |
| Result | |
| URL related to results and publications | |
| Number of participants that the trial has enrolled | |
| Results | |
| Results date posted | |
| Results Delayed | |
| Results Delay Reason | |
| Date of the first journal publication of results | |
| Baseline Characteristics | |
| Participant flow | |
| Adverse events | |
| Outcome measures | |
| Plan to share IPD | |
| IPD sharing Plan description | |
| Progress | |||||||
| Recruitment status | Completed | ||||||
| Date of protocol fixation |
|
||||||
| Date of IRB |
|
||||||
| Anticipated trial start date |
|
||||||
| Last follow-up date |
|
||||||
| Date of closure to data entry | |||||||
| Date trial data considered complete | |||||||
| Date analysis concluded | |||||||
| Other | |
| Other related information | |
| Management information | |||||||
| Registered date |
|
||||||
| Last modified on |
|
||||||
| Link to view the page | |
| URL(English) | https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000045243 |